Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma (GHSG-AFM13)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02321592
Recruitment Status : Recruiting
First Posted : December 22, 2014
Last Update Posted : November 6, 2017
Sponsor:
Collaborators:
Affimed GmbH
The Leukemia and Lymphoma Society
Information provided by (Responsible Party):
Prof. Dr. Andreas Engert, University of Cologne

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : August 2018
  Estimated Study Completion Date : December 2021